[Clinical evaluation of the role of gastrinemia and tumor tissue sensitivity to gastrin in cancer of the large intestines].
Tumor sensitivity to gastrin in vitro (52) and blood gastrin (112) were assayed in cases of colorectal cancer before surgery. Hypergastrinemia was detected in almost half the group of patients with large bowel tumors. It was found to aggravate the short-term and end results of treatment. At least half the tumors retained sensitivity to gastrin, with prognosis being favorable. It is suggested that medication be used for hormono-metabolic correction and measures be taken to suppress gastrin secretion.